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Background: Interstitial lung disease encompasses a diverse group of chronic lung conditions characterised by
distressing dyspnoea, fatigue, reduced exercise tolerance and poor health-related quality of life. Exercise training is
one of the few treatments to induce positive changes in exercise tolerance and symptoms, however there is
marked variability in response. The aetiology and severity of interstitial lung disease may influence the response to
treatment. The aims of this project are to establish the impact of exercise training across the range of disease
severity and to identify whether there is an optimal time for patients with interstitial lung disease to receive
exercise training.
Methods/Design: One hundred and sixteen participants with interstitial lung disease recruited from three tertiary
institutions will be randomised to either an exercise training group (supervised exercise training twice weekly for
eight weeks) or a usual care group (weekly telephone support). The 6-minute walk distance, peripheral muscle
strength, health-related quality of life, dyspnoea, anxiety and depression will be measured by a blinded assessor at
baseline, immediately following the intervention and at six months following the intervention. The primary
outcome will be change in 6-minute walk distance following the intervention, with planned subgroup analyses for
participants with idiopathic pulmonary fibrosis, dust-related interstitial lung disease and connective-tissue related
interstitial lung disease. The effects of disease severity on outcomes will be evaluated using important markers of
disease severity and survival, such as forced vital capacity, carbon monoxide transfer factor and pulmonary
hypertension.
Discussion: This trial will provide certainty regarding the role of exercise training in interstitial lung disease and will
identify at what time point within the disease process this treatment is most effective. The results from this study
will inform and optimise the clinical management of people with interstitial lung disease.
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The interstitial lung diseases (ILDs) are a disabling and
diverse group of chronic lung conditions that have been
broadly classified into four groups: ILD of known cause
such as occupational or environmental exposures and/or
collagen vascular disease; granulomatous ILD such as
sarcoidosis; idiopathic interstitial pneumonias including
idiopathic pulmonary fibrosis (IPF) and nonspecific
interstitial pneumonia (NSIP); and other rare forms of
ILD including lymphangioleiomyomatosis, pulmonary
Langerhans’ cell histiocytosis/histiocytosis X, and eosino-
philic pneumonia [1]. Many ILDs are characterised by
the development of irreversible and progressive interstitial
fibrosis of the lung parenchyma [2] resulting in altered
respiratory mechanics, impaired gas exchange, reduced
exercise capacity and dyspnoea on exertion [3-5]. Skeletal
muscle dysfunction and weakness may occur, leading to
worsening exercise capacity and increasing symptoms
[2,6,7]. Health-related quality of life (HRQoL) is frequently
markedly reduced and those with the greatest exercise
limitation report the worst quality of life [8]. As disease
progresses, severe hypoxemia and pulmonary hyperten-
sion may develop [9,10], with patients often becoming
dependent on supplemental oxygen.
The classification of the ILDs has been the subject of
criticism, due to its failure to reflect the marked hetero-
geneity in clinical course within disease subgroups.
Idiopathic pulmonary fibrosis (IPF), the best character-
ized of the ILDs, is largely a fatally progressive disease
with a median survival of 3–5 years [11]. The prognosis
of NSIP is more variable, and, although a minority of
patients may have an accelerated decline similar to IPF
[10], survival is generally significantly longer than in IPF.
Dust and connective tissue disease- related ILD may be
associated with a better overall survival rate but can
result in significant and progressive morbidity over many
years [12,13]. Prognosis of sarcoidosis is again variable
and difficult to predict with stabilisation or improvement
in some patients and the development of progressive
pulmonary fibrosis in others [10,14].
Few treatments have demonstrated improvements in
either HRQoL or community functioning for any of the
ILDs [15,16]. In IPF, the most common and most lethal
ILD, the options for pharmacological treatment are very
limited [11]. Therapies that can improve dyspnoea, fa-
tigue, exercise capacity and quality of life are highly
sought after in ILD [16]. Exercise is one of the few treat-
ments to show positive changes in functional capacity
and symptoms. We have previously shown that exercise
training could significantly improve exercise capacity
and reduce dyspnoea and fatigue symptoms in patients
with ILD of varying aetiology [17]. Nishiyama et al.
found similar positive effects from exercise training in
patients with IPF only [18]. Additionally, severalobservational studies evaluating the benefits of pulmon-
ary rehabilitation, of which exercise training is an essen-
tial component, demonstrated statistically and clinically
significant improvements in functional capacity, dys-
pnoea and HRQoL in patients with ILD of varying aeti-
ology [19-23]. Despite these promising outcomes
exercise training is not yet widely recommended for
people with ILD. Only weak recommendations regarding
exercise training are provided in the most recent clinical
guidelines for the diagnosis and management of IPF [11]
and ILD [10].
Uncertainty remains regarding the clinical relevance of
exercise training across the entire range of ILDs. Patients
with IPF appear to have smaller gains in functional cap-
acity than those with ILD of other aetiology [24]. This
raises the possibility that some forms of ILD may re-
spond to exercise training better than others. Common
manifestations of ILD, such as exercise induced hypoxia
and pulmonary hypertension [2,9], may also affect the
improvements that may be achieved. Hypoxaemia
impairs maximal exercise performance [3] and pulmon-
ary hypertension in ILD is associated with considerably
reduced exercise capacity and greater exercise limitation
[25-27]. In an uncontrolled study evaluating the relation-
ship between response to exercise and disease aetiology
and severity in forty-four subjects with ILD of varying
aetiology, less severe lung function, less oxyhaemoglobin
desaturation and less pulmonary hypertension were
associated with greater improvement in functional cap-
acity in patients with IPF [28]. This relationship per-
sisted at six months, suggesting that those with less
advanced IPF may be able to achieve sustained benefits
from exercise training. This relationship was not seen in
subjects with other ILDs. It is therefore possible that the
timing of exercise training may be important for patients
with IPF, whereas patients with other forms of ILD may
benefit regardless of disease severity.
In order for exercise training to be widely adopted in
clinical practice, clinicians require more information
regarding its role across the disease spectrum. The aims
of this study are 1) to establish the impact of exercise
training on ILDs of different aetiology and severity and
2) to identify whether there is an optimal timing for ex-
ercise training to achieve maximal benefit. We hypothe-
sise that exercise training will be effective regardless of
disease severity in patients with non-IPF related ILD,
whereas in patients with IPF, the response to exercise
training will be greatest in those with less severe disease.
Methods
Study design
This multi-centre randomised controlled trial will be
conducted at Alfred Health, Austin Health and Western
Health, Melbourne, Australia.
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Participants with a documented diagnosis of ILD will be
recruited for this study from the Departments of Re-
spiratory and Sleep Medicine at Alfred, Austin and
Western Health. The diagnosis of ILD will be made
according to established criteria. In IPF, the diagnostic
criteria will be consistent with those outlined in the
International Consensus Statement [11]. A surgical lung
biopsy will not be required for entry into the study as it
has been demonstrated that clinical and radiologic data
are sufficient to distinguish between IPF and other ILDs
in the hands of experienced clinicians [29]. Diagnosis of
connective tissue disease will be made according to the
rheumatological criteria for that disease; ILD in this set-
ting will be diagnosed according to clinical/radiologic
and lung function criteria, with lung biopsy in atypical
cases. Dust-related ILD will be confirmed according to
accepted criteria that include significant exposure to an
agent recognised to cause ILD and radiological confirm-
ation on high resolution computed tomography of the
chest, as determined by independent radiologists.
Participants must be clinically stable, ambulant, and
suffer from dyspnoea on exertion despite maximal ap-
propriate medical treatment. Participants will be
excluded if they 1) have a concurrent and predominant
diagnosis of another significant respiratory disorder (for
example: asthma, chronic obstructive pulmonary disease
[COPD], bronchiectasis, cystic fibrosis, or lung carcin-
oma) which is the primary cause of their symptoms; 2)
have a history of syncope on exertion; 3) are too unwell
to attend the hospital for exercise training; 4) have any
other co-morbidities, such as severe orthopaedic or
neurological deficits or unstable cardiac disease which
would prevent exercise training; 5) have participated in a
pulmonary rehabilitation program within the previous
12 months.
Sample size
One hundred and sixteen participants will be required
to detect a significant difference in the primary outcome
measure of change in functional exercise capacity (6-mi-
nute walk distance [6MWD]). This is based on the 80%
probability of detecting a difference in the change in
6MWD between the intervention and control group
using data from our previous randomised control trial
[17] and Cochrane review [24]. Our sample size calcula-
tion of 116 has been powered to include the required
number of participants in the three most commonly
observed ILD subgroups: IPF, dust-related ILD and con-
nective tissue disease-related ILD. To detect a true dif-
ference in the change in 6MWD in subjects with IPF, a
total of 72 subjects, 36 in each group, is required. This is
based on the lower limit of the range for the minimal
important difference (MID) of 29m [30] with a standarddeviation (SD) of 43m. To detect a true difference in the
change in 6MWD between groups using the upper limit
of the MID of 34m [30] with SD 43m, a total of 54 sub-
jects, 27 in each group, would be required. In subjects
with dust-related ILD, a total of 22 subjects, 11 in each
group, is required. This assumes that the true difference
between groups is 52m with SD of 40m. In subjects with
connective tissue disease-related ILD, 22 subjects, 11 in
each group, is required, assuming a difference of 38m
with SD 30m.
Data from our previous study [28] indicate that to de-
tect a relationship between carbon monoxide transfer
factor (TLCO) and change in 6MWD following pulmon-
ary rehabilitation with 80% power will require 31 sub-
jects in the pulmonary rehabilitation group. This
assumes that the true change in 6MWD is 15 meters for
each 10% change in baseline percent predicted TLCO.
To detect a relationship between degree of pulmonary
hypertension and change in 6MWD with 80% power will
require 35 subjects in the pulmonary rehabilitation
group. This assumes that the true change in 6MWD is
17 meters for each 10mmHg change in baseline right
ventricular systolic pressure.
Recruitment and randomisation
The flow of participants through the study will reflect
the recommendations from the Consolidated Standards
of Reporting Trials statement [31] and is outlined in
Figure 1. Participants will be identified at their regular
outpatient clinic appointments to the Departments of
Respiratory and Sleep Medicine at Alfred Health, Austin
Health and Western Health. Eligible participants will be
approached by the researchers who will explain the
study. Participants will receive written and verbal infor-
mation about the study and written consent will be
obtained from all participants. The Human Research
Ethics Committees of Alfred Health, Austin Health,
Western Health and La Trobe University approved the
study. The study protocol has been registered with the
Australian New Zealand Clinical Trials Registry
(ACTRN12611000416998).
Randomisation will be stratified according to the three
subgroups IPF, dust-related ILD and connective tissue
disease-related ILD. This will ensure that all subgroups
of ILD are evenly distributed between the intervention
and control groups. The randomisation will also be
stratified for disease severity according to TLCO <or
≥40% to ensure that those with severe disease are evenly
distributed between the intervention and control groups.
A set of permuted blocks will be generated for each of
the following subgroups: dust-related ILD, connective
tissue disease-related ILD, IPF with TLCO < 40% and
IPF with TLCO ≥ 40%. The random allocation sequence
will be generated using a computer generated random
Screened for Eligibility 
(All diagnoses of interstital lung disease)
Allocated to Exercise Training 
(Intervention)
Lost to follow up/
withdrawn from study 
(reason)
Lost to follow up/
withdrawn from study
(reason)
Follow up assessment at 9 weeks
Follow up assessment at 6 months
Analysed
Allocated to Usual Care 
(Control)
Lost to follow up/
withdrawn from study 
(reason)
Lost to follow up/
withdrawn from study
(reason)
Consent and baseline assessment
Stratified Randomisation
Ineligible:
- Failed inclusion criteria
- Met exclusion criteria
- Refused Consent
Figure 1 Flow of patients through the study.
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achieved by giving the responsibility for allocation se-
quence generation and group allocation to a researcher
independent of the study and its investigators. The
group allocation will be kept in sealed, opaque envel-
opes in a central location. Following the baseline as-
sessment, participants will be randomly allocated to
either the exercise training group or to a control group
by a researcher, who is not involved in the recruitment
or assessment of the participants or the execution of
the intervention, by opening the sealed opaque
envelope.Intervention
Exercise training group
The exercise training group will undergo a twice-weekly
supervised exercise training program at the institution
where they were recruited for a period of 8 weeks. The
exercise program will follow the pulmonary rehabilita-
tion guidelines for exercise prescription in chronic lung
disease [32]. Each session will consist of 30 minutes of
aerobic exercise plus upper and lower limb resistance
training exercises. The aerobic exercise component will
comprise of 15 minutes each of stationary cycling and
walking, either on the treadmill or along a corridor. The
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of the peak walking speed (km/hr) achieved on the
6-minute walk test (6MWT). The initial intensity of the
stationary cycling will be prescribed at 70% of their max-
imum work rate estimated from their 6MWT [33] and
will be adjusted to elicit a rating of perceived exertion
(RPE) of 12–14 on the 6–20 Borg scale and a dyspnoea
score of 3–4 on the modified Borg scale [34]. The dur-
ation of exercise on each modality will be adjusted if the
participant has a co-morbidity that limits their capability
on one specific modality, however the total exercise time
will remain at 30 minutes. Interval training will be used
for those participants who are unable to tolerate con-
tinuous exercise. The resistance program will comprise
three lower limb and four upper limb dumbbell exer-
cises. The initial load will correspond to 10-12RM (repe-
tition maximum), that is, a weight that can be lifted
correctly and comfortably at least 10 times, but not
more than 12 times and elicits a RPE of 12–14 on the
6–20 Borg scale [35,36]. All exercise modalities will be
progressed regularly by an experienced exercise physi-
ologist or physiotherapist to maintain dyspnoea and
fatigue scores of 3–4 and a RPE score of 12–14. Supple-
mental oxygen will be provided during training if SpO2
on room air is <88% whilst exercising and will be titrated
to maintain a SpO2 ≥90%.
Once the participant is safely established on a super-
vised exercise regimen, an unsupervised home exercise
program will be prescribed as per current Pulmonary
Rehabilitation guidelines [37] to achieve three additional
home-based exercise sessions per week. Participants will
be educated on how to monitor their symptoms and
their level of exertion at home and will be instructed to
exercise at an intensity similar to that achieved in the
supervised sessions. Participants will record their exer-
cise session in an exercise diary and this diary will be
reviewed weekly by the supervising clinician. At the con-
clusion of the 8-week program, participants will be
instructed to continue with their home exercise program
four to five times per week thereafter [32,38,39]. Attend-
ance at 12 out of 16 sessions will be considered comple-
tion of the intervention.
Usual care group
Participants randomised to the usual care group will not
undergo any supervised exercise training and will not re-
ceive any recommendations regarding exercise training
or physical activity. These participants will be contacted
once weekly by telephone for the duration of the 8 week
intervention period to provide general support and
health advice and to answer any queries or concerns the
participants may have. These phone calls will be con-
ducted according to a standardised script. This is a com-
monly used control for exercise training interventionsand was used in our earlier randomised controlled trial
in ILD [17]. The participants in the usual care group will
be offered exercise training at the conclusion of the 6
month follow-up period.
Outcome measures
Outcome measures will be collected at baseline, upon
completion of the intervention period (nine weeks) and
at six months following completion of the intervention
(Figure 1). A six month follow-up period is the longest
we consider to be clinically feasible without excessive
loss of participants due to clinical decline and death. At
baseline, data collection will include age, gender, body
mass index, past medical history, smoking history, use of
oxygen therapy, current pharmological treatment and all
of the following outcome measures.
Primary outcome measure
1. Change in functional exercise capacity will be
measured with 6MWT according to standardised
criteria [40]. Two tests will be conducted separated
by a 30-minute rest period and the best result
recorded. Supplemental oxygen will be used during
both 6MWTs in participants who already have
exertional oxygen or for those who have resting
SpO2 <88%. Supplemental oxygen will be used at a
flow rate of 4L.min-1 for the second test if SpO2
<85% during the first 6MWT [41-43]. Follow up tests
will be conducted on the same oxygen flow rate. The
primary outcome is change in 6MWD from baseline
to nine weeks. Six-minute walk distance has been
shown to correlate strongly with maximum exercise
capacity (VO2peak) in IPF and has shown
responsiveness to change following pulmonary
rehabilitation in IPF [18] and ILD [17].
Secondary outcome measures
1. Peripheral muscle strength will be assessed using a
hand held dynamometer (Commander Power track
II, JTech Medical, Utah, USA). Three maximal
isometric contractions of the elbow flexors and knee
extensors on the dominant side will be tested.
Skeletal muscle weakness, in particular quadriceps
weakness, has been shown to correlate strongly with
reduced exercise tolerance and exercise capacity in
patients with ILD [18,44] and was found to be an
independent predictor of exercise capacity at peak
exercise in patients with IPF [18]. This measure will
assess the contribution of muscle strength changes to
changes in exercise tolerance.
2. Health-related Quality of Life (HRQoL) will be
measured using the Chronic Respiratory Disease
Dowman et al. BMC Pulmonary Medicine 2013, 13:8 Page 6 of 8
http://www.biomedcentral.com/1471-2466/13/8Questionnaire (CRQ), and St George Respiratory
Questionnaire idiopathic pulmonary fibrosis specific
version (SGRQ-I). The CRQ has been validated
previously in ILD [8] and has demonstrated
improvements following exercise training in ILD
[17]. The SGRQ-I is designed to be more responsive
in patients with IPF than the original St George
respiratory questionnaire (SGRQ) and has similar
psychometric properties to the original SGRQ [45].
3. Dyspnoea will be measured using the University of
California San Diego Shortness of Breath
Questionnaire (UCSD SOBQ) and the Modified
Medical Research Council dyspnoea scale (MMRC).
The UCSD SOBQ comprises 24 items that assess
dyspnoea over the preceding week and is a reliable
and valid instrument used to assess dyspnoea
associated with Activities of Daily Living (ADL)s in
patients with chronic lung disease [46-48]. The
MMRC is a valid measure of breathlessness and
symptom severity in ILD [49,50].
4. Anxiety and Depression will be measured using the
Hospital Anxiety and Depression Scale (HADS). The
HADS has been designed to detect and measure the
severity of anxiety and depression and has been
shown to be a reliable instrument in evaluating
anxiety and depression in IPF and ILD [51,52].
5. The Global Rating of Change Scale will be used to
assess the participants’ self-perceived improvement
or deterioration over time. The Global rating of
change scale involves asking the participant whether
there has been any change in their symptoms or
walking ability since their commencement in the
study [53]. Participants can answer either ‘worse’,
‘about the same’ or ‘better’. If subjects state that they
are worse or better they are asked to grade how
much worse or better on a Likert scale from one to
seven. The global rating of change has been used to
establish the minimal important difference for the
6MWD in people with ILD [30].
At 9 weeks and at 6 months follow up participants will
undergo repeat measurements of the 6MWT, peripheral
muscle strength, CRQ, SGRQ-I, UCSD SOBQ, MMRC,
HADS and Global Rating of Change to evaluate the im-
mediate and long term effects of exercise training. An
independent assessor, blinded to group allocation, will
perform all outcome assessments.
Classification of disease severity
1. Respiratory function testing will be performed in
accordance with the American Thoracic Society
guidelines [54] to quantify disease severity and to
assess any clinical change in respiratory function overtime. Standard spirometric measures will include
forced vital capacity (FVC) and forced expiratory
volume in one second (FEV1) and will be performed
at baseline and at six months follow up. Carbon
monoxide transfer factor will be measured at baseline
and at six months follow up. Static lung volumes
measured via plethysmography will be measured at
baseline only and will include total lung capacity
(TLC), functional residual capacity (FRC) and
residual volume (RV).
2. Pulmonary Hypertension will be assessed by a trans-
thoracic echocardiogram. Pulmonary hypertension is
a common complication of ILD [4,9] and patients
with concomitant pulmonary hypertension are likely
to have greater exercise impairment.
The respiratory function tests and transthoracic echo-
cardiogram will be performed by routine clinical
personnel at the treating hospital and they will be un-
aware of the group allocation.
Statistical analysis
Data will be analysed using intention-to-treat principles,
with inclusion of all available data regardless of whether
the intervention is completed. The response of exercise
training and control groups will be compared for change
in exercise and HRQoL variables using linear mixed
model analyses. Planned subgroup analyses will be con-
ducted for participants with IPF, dust-related ILD and
connective tissue-related ILD. Multiple regression ana-
lysis will be undertaken to establish which subjects re-
spond best to exercise training and when this treatment
should be offered, with change in 6MWD following ex-
ercise training as the dependent variable. Baseline demo-
graphic and physiological variables such as age; gender;
disease aetiology; percent predicted TLC; percent pre-
dicted FVC; TLCO; pulmonary artery pressure; and the
extent of oxyhaemoglobin desaturation during exercise
will be used as predictors.
Discussion
Interstitial lung disease represents a heterogeneous
group of chronic, disabling lung disorders [55] which are
associated with significant dyspnoea and fatigue, reduced
exercise capacity and diminished quality of life [2]. The
ILDs are an important cause of respiratory morbidity
and mortality across the globe however treatment
options for people with ILD are extremely limited. Exer-
cise training is a simple intervention that has the poten-
tial to impact outcomes that are of utmost importance
to patients [2,16]. Currently exercise training has not
been made widely available to patients with ILD, due to
variability in outcomes and doubts regarding its efficacy
across the spectrum of disease. There is little evidence
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ercise and what is the best timing for exercise training
to occur. The type and severity of ILD may be important
determinants. It is possible that people with IPF may re-
ceive greater benefits if exercise training is undertaken
earlier in their disease course and people with other
ILDs will receive benefits regardless of the severity of
their disease. However there is no robust, adequately
powered evidence to confirm this position.
The most recent published guidelines on IPF [11] pro-
vide only a weak recommendation for pulmonary re-
habilitation as part of managing IPF due to low quality
of evidence concerning the benefit of pulmonary re-
habilitation in this particular form of ILD. Although they
indicate there is moderate quality data demonstrating
improvement in functional status and patient-centered
outcome, uncertainty still remains regarding duration of
benefit and further research is needed to impact on the
strength of this recommendation. Similarly the Intersti-
tial Lung Disease Guidelines [10] ascribe a low level of
evidence to pulmonary rehabilitation, indicating that
there is need for more information before pulmonary re-
habilitation can be confidently adopted as a recom-
mended treatment for all ILD patients.
This study has been designed to define the role and
impact of exercise training in ILD across the range of
disease severity and aetiology and to identify whether an
optimal time exists during which exercise training
should take place in order to ensure that maximal bene-
fit can be obtained. This study will provide patients and
clinicians with certainty regarding the role of exercise
training as well as the magnitude and duration of
expected benefits. If this trial provides evidence of bene-
fit, it will provide a scientific rationale for pulmonary re-
habilitation to be considered standard care for people
with ILD.
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